Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edgewise Therapeutics (EWTX) Other Non-Current Assets (2020 - 2025)

Edgewise Therapeutics has reported Other Non-Current Assets over the past 6 years, most recently at $695000.0 for Q1 2025.

  • Quarterly results put Other Non-Current Assets at $695000.0 for Q1 2025, changed N/A from a year ago — trailing twelve months through Mar 2025 was $695000.0 (changed N/A YoY), and the annual figure for FY2024 was $262000.0, down 24.71%.
  • Other Non-Current Assets reached $695000.0 in Q1 2025 per EWTX's latest filing, up from $262000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $695000.0 in Q1 2025 and bottomed at $201000.0 in Q1 2021.
  • Median Other Non-Current Assets over the past 5 years was $295000.0 (2021), compared with a mean of $368733.3.
  • The largest annual shift saw Other Non-Current Assets surged 178.11% in 2022 before it tumbled 55.1% in 2023.
  • Over 5 years, Other Non-Current Assets stood at $548000.0 in 2021, then plummeted by 54.2% to $251000.0 in 2022, then soared by 38.65% to $348000.0 in 2023, then dropped by 24.71% to $262000.0 in 2024, then surged by 165.27% to $695000.0 in 2025.
  • Business Quant data shows Other Non-Current Assets for EWTX at $695000.0 in Q1 2025, $262000.0 in Q4 2024, and $262000.0 in Q3 2024.